Berberine: The Natural Antidote to Metabolic Derangement?

Berberine, an orangish-yellow alkaloid found at high levels in the bark and root structures of many ground-covering berberineshrubs, has an extensive history of use as a medicinal herb in North America, Europe, Asia, and India. Oregon grape, a North American source of berberine, was used by the native inhabitants and European colonists in the Pacific Northwest as a “blood toner,” an antimicrobial, and to ease digestive distress.[1] Berberine has now become well known for its impact on metabolic function, and the issues associated with metabolic syndrome, conditions which were nary a thought for the natives and colonists who first inhabited the Northwest.

Research on the topic of berberine as an anti-hyperglycemic agent began in the late 1980’s when its blood sugar-lowering effect was discovered while it was being used for the treatment of a diabetic patient with diarrhea.[2] Since the early days of berberine research, multiple clinical trials have been performed investigating the use of berberine for a range of metabolic derangements. A 2015 meta-analysis of twenty-seven clinical trials concludes “berberine has comparable therapeutic effect on type 2 diabetes mellitus, hyperlipidemia and hypertension with no serious side effect,”[3] substantiating the use of berberine for patients with metabolic syndrome.

Berberine and the Gut

The systemic effects of berberine are in part mediated via the gut. Berberine promotes the growth of a bacteria known as Akkermansia muciniphila,[4] which, interestingly enough, metformin has also been shown to increase.[5] A. muciniphila has been shown to positively impact weight gain, fat mass, and glucose metabolism. Higher levels of this normal flora exist in athletes and individuals with a low body mass index (BMI),[6] and low levels have been observed in patients with impaired glucose metabolism and obesity.[7],[8] Animal studies have shown that administration of A. muciniphila not only reverses the metabolic effects of high-fat diet feeding, but also increases the intestinal levels of endocannabinoids, which play a role in controlling inflammation and the integrity of the gut barrier.[9]

Berberine affects the balance of the other bacteria in the gut as well, helping to reduce intestinal permeability[10],[11] and with this decreasing systemic levels of endotoxin, a contributor to inflammation, hepatocyte damage, and the development of atherosclerosis.[12],[13] Berberine has evidence of exerting a tonifying effect on gastrointestinal motility – increasing motility and contractility in states of hypofunction, and relaxing the system when it is in an excessively contractile state.[14] Berberine has an antinociceptive effect, which may be in part due to its impact on contractility, or mediated via its interactions with the endogenous opioid system,[15] or via nitric oxide synthesis.[16] Berberine increases the gut production of short chain fatty acids (SCFAs), in particular butyrate,[17] which has anti-inflammatory effects in the colon and beyond.[18]

Mechanisms by Which Berberine Impacts Glucose and Cholesterol Balance

Besides the impact that shifts in the gut microbial balance may have on metabolic health, there are many mechanisms by which berberine may affect glucose and lipid metabolism. Berberine activates adenosine monophosphate–activated protein kinase (AMPK), a fuel-sensing enzyme that is present in all mammalian cells.[19],[20] When activated, AMPK stimulates energy-generating processes within the cell such as glucose uptake and decreases energy consuming processes such as lipid synthesis, leading to a reduction in blood sugar levels and cholesterol production.[21],[22] Activation of AMPK by berberine also reduces inflammation,[23] promotes vasodilation,[24] and inhibits vasculature changes which contribute to stenosis.[25]

In addition to AMPK activation, the mechanisms via which berberine may positively impact blood sugar regulation are multifold. Berberine has been shown in cellular and/or animal studies to improve cellular sensitivity to insulin[26] and glucose uptake,[27] increase insulin secretion,[28] inhibit gluconeogenesis,[29] decrease gastrointestinal glucose absorption,[30] and increase glycolysis.[31]

Several mechanisms via which berberine may improve cholesterol balance also have been described. Berberine has been shown to inhibit cholesterol absorption,[32],[33] and increase its excretion.[34] Berberine increases the expression of low-density lipoprotein (LDL) receptors in the liver, which promotes bile formation and secretion, and along with this, cholesterol.[35] In the setting of hyperhomocysteinemia, common in cardiovascular disease and type 2 diabetes,[36],[37] berberine was also observed to inhibit HMG-CoA reductase activity and reduce hepatic cholesterol content.[38]

Increased cholesterol excretion also may occur due to berberine’s interaction with the bile acid farnesoid X receptor (FXR) in the intestinal epithelial cells.[39] Interaction with FXR increases excretion of conjugated bile acids in the feces and reduces the accumulation of hepatic triglycerides and the development of HFD-associated obesity.

Clinical Evidence of Berberine’s Impact on Diabetes and Dysglycemia

The impact of berberine on glucose and cholesterol regulation has been the topic of multiple clinical studies. In one double-blind, placebo-controlled study, 116 patients with newly-diagnosed type 2 diabetes and dyslipidemia (without previous treatment) were randomized to receive either berberine at a dosage of 500 mg twice daily or placebo.[40] After three months, significant decreases were seen in fasting blood glucose (FBG) from 126 ± 14 to 101 ± 16 mg/dL, postprandial blood glucose (PPG) from 216 ± 49 to 160 ± 50 mg/dL, hemoglobin A1c (HbA1c) from 7.5 ± 1.0 to 6.6 ± 0.7%, total cholesterol from 205 ± 38 to 168 ± 37 mg/dL, and LDL cholesterol from 125 ± 31 to 99 ± 30 mg/dL in individuals receiving berberine compared to placebo (P < 0.0001 for all). Triglycerides also were significantly reduced compared to placebo (P = 0.001) from 222 ± 181 to 143 ± 97 mg/dL.

In another study consisting of newly-diagnosed type 2 diabetics, at a dosage of 500 mg three times daily berberine was found have effects identical to an equivalent dosage of metformin, significantly reducing HbA1c from 9.5 ± 0.5% to 7.5 ± 0.4%, FBG from 191 ± 16 mg/dL to 124 ± 9 mg/dL, and PPG from 357 ± 30.6 to 200 ± 16 mg/dL (P < 0.01 for all) after a period of three months.[41] Triglycerides and total cholesterol also were significantly decreased (P < 0.05). With both metformin and berberine, the most dramatic changes in FBG and PPG were seen within the first two weeks, with minor improvements and approximately stable levels beyond this time.

The second arm of this study involved the treatment of poorly-controlled type 2 diabetics (HbA1c of >7.0%). In these individuals, 500 mg of berberine three times daily was added to their current regime. In this population, the benefits of berberine were seen as soon as 7 days, with the FBG declining from 173 ± 49 to 141 ± 32 mg/dL (P < 0.001) by day 7, stabilizing at approximately 135 mg/dL for the remainder of the 3-month period. By 5 weeks, their HbA1c significantly decreased from 8.1% to 7.3% (P < 0.001), without significant change thereafter. The parameters of fasting insulin and homeostatic model assessment of insulin resistance (HOMA-IR) also showed improvement, decreasing by 29.0% (P < 0.01) and 46.7% (P < 0.001), respectively. Triglycerides, total cholesterol and LDL cholesterol also were significantly reduced.

A 2013 meta-analysis of eleven randomized controlled trials on the topic of berberine and dyslipidemia well summarizes the additional clinical studies, finding significant reduction in total cholesterol, triglycerides, and LDL cholesterol, as well as a significant increase in high-density lipoprotein (HDL) cholesterol.[42] Improvements in triglycerides likely play into the reduction of hepatic fat content which has been seen in individuals with non-alcoholic fatty liver disease (NAFLD) as well.[43]

Medication Interactions and Adverse Reactions

One cautionary note which must be remembered in practice is that berberine, at commonly used doses, moderately inhibits cytochrome P450 3A4 (CYP3A4), CYP2D6, and CYP2C9,[44],[45] which may lead to increased levels of commonly used medications including lovastatin, clarithromycin, sildenafil, losartan, venlafaxine, and metoprolol as well as many others. Because berberine affects the flora balance in the gut, transient gastrointestinal symptoms (nausea, diarrhea, constipation, abdominal distension, abdominal pain) may occur, however no other adverse effects have been noted. However, berberine generally has a positive impact overall on gastrointestinal health, often being used as a therapy when there is a state of dysbiosis such as small intestinal bacterial overgrowth (SIBO).[46]

The research on berberine extends far beyond metabolic health, and extends to topics of cardiovascular disease, malignancy, dementia, osteoporosis, and mental illness as well.[47] Clearly, this alkaloid has a high level of biological activity, and its use may combat the metabolic issues which many face.

Dr. Carrie Decker, ND graduated with honors from the National College of Natural Medicine (now the National University of Natural Medicine) in Portland, Oregon. Dr. Decker sees patients remotely, with a focus on gastrointestinal disease, mood imbalances, eating disorders, autoimmune disease, and chronic fatigue. Prior to becoming a naturopathic physician, Dr. Decker was an engineer, and obtained graduate degrees in biomedical and mechanical engineering from the University of Wisconsin-Madison and University of Illinois at Urbana-Champaign respectively. Dr. Decker continues to enjoy academic research and writing and uses these skills to support integrative medicine education as a writer and contributor to various resources. Dr. Decker supports Allergy Research Group as a member of their education and product development team.

[1] Matthews HB, Lucier GW, Fisher KD. Medicinal herbs in the United States: research needs. Environ Health Perspect. 1999 Oct;107(10):773-8.
[2] Yin J, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002 Nov;51(11):1439-43.
[3] Lan J, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015 Feb 23;161:69-81.
[4] Zhu L, et al. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe-/- mice. Atherosclerosis. 2018 Jan;268:117-126.
[5] de la Cuesta-Zuluaga J, et al. Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid-Producing Microbiota in the Gut. Diabetes Care. 2017 Jan;40(1):54-62.
[6] Clarke SF, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014 Dec;63(12):1913-20.
[7] Escobar JS, et al. The gut microbiota of Colombians differs from that of Americans, Europeans and Asians. BMC Microbiol. 2014 Dec 14;14:311.
[8] Dao MC, et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut. 2016 Mar;65(3):426-36.
[9] Everard A, et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci U S A. 2013 May 28;110(22):9066-71.
[10] Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit 2011;17:RA164-167.
[11] Gu L, et al. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis. 2011 Jun 1;203(11):1602-12.
[12] Moseley RH, et al. Effect of endotoxin on bile acid transport in rat liver: a potential model for sepsis-associated cholestasis. Am J Physiol. 1996 Jul;271(1 Pt 1):G137-46.
[13] Konev IuV, Lazebnik LB. [Endotoxin (LPS) in the pathogenesis of atherosclerosis]. Eksp Klin Gastroenterol. 2011;(11):15-26.
[14] Chen DP, et al. Effects of berberine on rat jejunal motility. J Pharm Pharmacol. 2013 May;65(5):734-44.
[15] Feng Y, et al. Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. Phytother Res. 2013 Oct;27(10):1564-71.
[16] Tang QL, et al. Antinociceptive effect of berberine on visceral hypersensitivity in rats. World J Gastroenterol. 2013 Jul 28;19(28):4582-9.
[17] Wang Y, et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017 May;70:72-84.
[18] Stilling RM, et al. The neuropharmacology of butyrate: The bread and butter of the microbiota-gut-brain axis? Neurochem Int. 2016 Oct;99:110-132.
[19] Lee YS, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006 Aug;55(8):2256-64.
[20] Kim WS, et al. Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity. Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E812-9.
[21] Viollet B, et al. Targeting AMP-activated protein kinase as a novel therapeutic approach for the treatment of metabolic disorders. Diabetes Metab. 2007 Dec;33(6):395-402.
[22] Brusq JM, et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res. 2006 Jun;47(6):1281-8.
[23] Jeong HW, et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009 Apr;296(4):E955-64.
[24] Wang Y, et al. Berberine prevents hyperglycemia-induced endothelial injury and enhances vasodilatation via adenosine monophosphate-activated protein kinase and endothelial nitric oxide synthase. Cardiovasc Res. 2009 Jun 1;82(3):484-92.
[25] Liang KW, et al. Berberine inhibits platelet-derived growth factor-induced growth and migration partly through an AMPK-dependent pathway in vascular smooth muscle cells. Eur J Pharmacol. 2008 Aug 20;590(1-3):343-54.
[26] Ko BS, et al. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005 Aug;28(8):1431-7.
[27] Yin J, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002 Nov;51(11):1439-43.
[28] Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 2004 Apr;25(4):496-502.
[29] Jiang SJ, et al. Berberine inhibits hepatic gluconeogenesis via the LKB1-AMPK-TORC2 signaling pathway in streptozotocin-induced diabetic rats. World J Gastroenterol. 2015 Jul 7;21(25):7777-85.
[30] Pan GY, et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 2003 Jul;69(7):632-6.
[31] Yin J, et al. Berberine improves glucose metabolism through induction of glycolysis. Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E148-56.
[32] Wang Y, et al. Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption. Metabolism. 2014 Sep;63(9):1167-77.
[33] Wang Y, et al. Berberine and plant stanols synergistically inhibit cholesterol absorption in hamsters. Atherosclerosis. 2010;209:111–7.
[34] Li XY, et al. Effect of berberine on promoting the excretion of cholesterol in high-fat diet-induced hyperlipidemic hamsters. J Transl Med. 2015;13:278.
[35] Briand F, et al. Upregulating reverse cholesterol transport with cholesteryl ester transfer protein inhibition requires combination with the LDL-lowering drug berberine in dyslipidemic hamsters. Arterioscler Thromb Vasc Biol. 2013 Jan;33(1):13-23.
[36] McCully KS. Homocysteine and the pathogenesis of atherosclerosis. Expert Rev Clin Pharmacol. 2015 Mar;8(2):211-9.
[37] Ndrepepa G, et al. Circulating homocysteine levels in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2008 Jan;18(1):66-73.
[38] Wu N, et al. Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia. Am J Physiol Regul Integr Comp Physiol. 2011 Mar;300(3):R635-43.
[39] Sun R, et al. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. Mol Pharmacol. 2017 Feb;91(2):110-122.
[40] Zhang Y, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008 Jul;93(7):2559-65.
[41] Yin J, et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008 May;57(5):712-7.
[42] Dong H, et al. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013 Apr;79(6):437-46.
[43] Yan HM, et al. Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease. PLoS One. 2015 Aug 7;10(8):e0134172.
[44] Wu X, et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005 Sep;61(8):567-72.
[45] Guo Y, et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012 Feb;68(2):213-7.
[46] Decker C. Treatment of Small Intestinal Bacterial Overgrowth with Botanical Therapies Equivalent to Rifaximin. Integrative Medicine Alert. 2015 Aug 1;18(8).
[47] Imenshahidi M, et al. Berberis Vulgaris and Berberine: An Update Review. Phytother Res. 2016 Nov;30(11):1745-1764.